5%咪喹莫特乳膏治疗浅表型婴儿血管瘤的临床疗效研究

Clinical implication of 5% imiquimod cream for the treatment of infantile hemangiomas superficial

目的:5%咪喹莫特乳膏(明欣利迪,四川明欣药业提供,批号:10091)作为一种新的免疫调节剂在国内已开始用于多种疾病的治疗,本研究旨在观察咪喹莫特治疗浅表型婴儿血管瘤的疗效。方法:60例浅表型婴幼儿血管瘤,平均年龄在17周,每周三次外用5%咪喹莫特乳膏,至一岁时,观察用药前后对比疗效和不良反应发生情况。治疗的消退程度以百分数计算,并比较IH各临床表型间有效率的统计学差异,用χ2检验。结果:60浅表型婴儿血管瘤(IH)的有效率为75%,使用前后疗效有统计学差异。不良反应主要为轻微皮肤红斑。结论:外用5%咪喹莫特乳膏对浅表型婴儿血管瘤有明显的疗效且使用安全,不良反应轻微。

Objective ：5% Imiquimod cream （ Mingxinlidi, Chuan Mingxin Pharmaceutical provided, Batch number： 10091 ） , a no- vel immune response modifier, has been used for the treatment of many diseases in the country. This study aims to explore the clinical implication and side effects of imiquimod in the treatment of superficial IH. Methods ：60 children suffered from superfical IH with the average age of 17 weeks were treated with 5% imiquimod cream. The clinical efficacy and side effects were evaluated at one year of age. The regression of treatment calculated as a percentage, and compared the clinical phenotype IH efficient statistical difference be- tween using X2 test. Results：The effective rate was 75% with a statistically significant improvement. Slight dermal erythema was the most common side effects. Conclusion： Imiquimod cream is effective and safe in superficial IH , adverse reactions are mild.